专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2015134894A1 ANTI-C5 ANTIBODIES HAVING IMPROVED PHARMACOKINETICS 审中-公开
标题翻译：具有改善药物动力学的抗C5抗体
公开(公告)号：WO2015134894A1
公开(公告)日：2015-09-11
申请号：PCT/US2015/019225
申请日：2015-03-06
申请人： ALEXION PHARMACEUTICALS, INC.
发明人： ANDRIEN, Bruce, A. , SHERIDAN, Douglas, L. , TAMBURINI, Paul, P.
IPC分类号： C07K16/18 , C07K16/40 , A61P29/00 , A61P37/06
CPC分类号： C07K16/18 , A61K38/00 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K16/28 , C07K16/40 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/35 , C07K2317/41 , C07K2317/52 , C07K2317/526 , C07K2317/56 , C07K2317/565 , C07K2317/64 , C07K2317/72 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
摘要翻译：本公开提供的抗体尤其可用于抑制末端补体（例如，C5b-9 TCC的组装和/或活性）和C5a过敏毒素介导的炎症，从而治疗补体相关疾病。所述抗体相对于环丙沙星具有许多改善的性质，包括例如人的血清半衰期增加。

2. 发明申请

WO2019126536A1 HUMANIZED ANTI-CD200 ANTIBODIES AND USES THEREOF 审中-公开
公开(公告)号：WO2019126536A1
公开(公告)日：2019-06-27
申请号：PCT/US2018/066855
申请日：2018-12-20
申请人： ALEXION PHARMACEUTICALS INC.
发明人： MACK, Taneisha, Ann-Tanara , SHERIDAN, Douglas, L. , PANAVAS, Tadas
IPC分类号： C07K16/28 , A61P37/06 , A61P35/00 , A61K39/395
CPC分类号： C07K16/2803 , A61P35/00 , A61P37/06 , C07K2317/24 , C07K2317/55 , C07K2317/92 , C07K2317/94
摘要： Provided herein are antibodies, or antigen binding portions thereof, that bind to CD200. Also provided are uses of these proteins in therapeutic applications, such as the treatment of cancer and in conjunction with organ transplantation. Also provided are nucleic acids encoding the heavy and/or light chain variable regions (or heavy and/or light chains) of the antibodies, vectors comprising the nucleic acids, and cells that produce the antibodies.

3. 发明申请

WO2019014360A1 POLYPEPTIDES THAT BIND COMPLEMENT COMPONENT C5 OR SERUM ALBUMIN AND FUSION PROTEINS THEREOF 审中-公开
公开(公告)号：WO2019014360A1
公开(公告)日：2019-01-17
申请号：PCT/US2018/041661
申请日：2018-07-11
申请人： ALEXION PHARMACEUTICALS, INC.
发明人： PUFFER, Bridget , CHANDLER, Julian , GERA, Nimish , SHERIDAN, Douglas, L. , JINDAL, Siddharth , TAMBURINI, Paul, P.
IPC分类号： C07K16/46 , A61K39/395 , C07K16/18
摘要： The disclosure provides engineered polypeptides that specifically bind to human complement component C5 and/or serum albumin. The disclosure also provides fusion proteins comprising such engineered polypeptides, wherein such fusion proteins may be multivalent and multi- specific fusion proteins. The disclosure further provides nucleic acid molecules that encode such engineered polypeptides or fusion proteins, and methods of making such engineered polypeptides or fusion proteins. The disclosure further provides pharmaceutical compositions that comprise such engineered polypeptides or fusion proteins, and methods of treatment using such engineered polypeptides or fusion proteins.

4. 发明申请

WO2020092549A1 SUBCUTANEOUS DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) 审中-公开
公开(公告)号：WO2020092549A1
公开(公告)日：2020-05-07
申请号：PCT/US2019/058846
申请日：2019-10-30
申请人： ALEXION PHARMACEUTICALS, INC.
发明人： VOLLES, Lori , PRADHAN, Rajendra , SHERIDAN, Douglas, L. , VALLEE, Marc , GAO, Xiang
IPC分类号： A61P7/00 , C07K16/18 , A61K39/395
摘要： Provided are methods for clinical treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) comprising administering to the patient an anti-C5 antibody, or antigen binding fragment thereof, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered (or is for administration) subcutaneously according to a particular clinical dosage regimen ( i.e ., at a particular dose amount and according to a specific dosing schedule). In one embodiment, the patient has previously been treated with eculizumab (Soliris®).

5. 发明申请

WO2019014360A8 POLYPEPTIDES THAT BIND COMPLEMENT COMPONENT C5 OR SERUM ALBUMIN AND FUSION PROTEINS THEREOF 审中-公开
公开(公告)号：WO2019014360A8
公开(公告)日：2019-01-17
申请号：PCT/US2018/041661
申请日：2018-07-11
申请人： ALEXION PHARMACEUTICALS, INC.
发明人： PUFFER, Bridget , CHANDLER, Julian , GERA, Nimish , SHERIDAN, Douglas, L. , JINDAL, Siddharth , TAMBURINI, Paul, P.
IPC分类号： C07K16/46 , A61K39/395 , C07K16/18
摘要： The disclosure provides engineered polypeptides that specifically bind to human complement component C5 and/or serum albumin. The disclosure also provides fusion proteins comprising such engineered polypeptides, wherein such fusion proteins may be multivalent and multi- specific fusion proteins. The disclosure further provides nucleic acid molecules that encode such engineered polypeptides or fusion proteins, and methods of making such engineered polypeptides or fusion proteins. The disclosure further provides pharmaceutical compositions that comprise such engineered polypeptides or fusion proteins, and methods of treatment using such engineered polypeptides or fusion proteins.

6. 发明申请

WO2013177035A2 HUMANEERED ANTI-FACTOR B ANTIBODY 审中-公开
标题翻译：人类抗原B抗体
公开(公告)号：WO2013177035A2
公开(公告)日：2013-11-28
申请号：PCT/US2013/041811
申请日：2013-05-20
申请人： ALEXION PHARMACEUTICALS, INC.
发明人： HUNTER, Jeffrey, W. , SHERIDAN, Douglas, L.
IPC分类号： A61K39/395
CPC分类号： C07K16/18 , C07K2317/41 , C07K2317/92
摘要： This invention relates to humaneered anti-factor B antibodies and antigen-binding fragments thereof with modified glycosylation patterns. The humaneered anti-factor B antibodies and antigen-binding fragments thereof are derived from murine monoclonal antibody 1379, which binds factor B in the third short consensus repeat ("SCR") domain and selectively inhibits activation of the alternative complement pathway by preventing formation of the C3bBb complex. The invention also relates to methods of treating diseases or disorders in which activation of the alternative complement pathway plays a role, and methods of selectively inhibiting activation of the alternative complement pathway in an individual in need thereof.
摘要翻译：本发明涉及具有改变的糖基化模式的人性化抗因子B抗体及其抗原结合片段。人类的抗因子B抗体及其抗原结合片段衍生自鼠单克隆抗体1379，其在第三短共有重复（“SCR”）结构域中结合因子B，并通过预防形成的方法选择性地抑制替代补体途径的活化 C3bBb复合物。本发明还涉及治疗其中补体途径的活化起作用的疾病或病症的方法，以及在有需要的个体中选择性抑制替代补体途径活化的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式